FDA Approves Genentech ’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)

RVO is the third indication for Vabysmo, in addition to wet, or neovascular, age-related macular degeneration and diabetic macular edema Approval is based on two Phase III studies demonstrating early and sustained vision improvements that were...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news